HUE045156T2 - Gyógyászati dózisformák - Google Patents

Gyógyászati dózisformák

Info

Publication number
HUE045156T2
HUE045156T2 HUE14819084A HUE14819084A HUE045156T2 HU E045156 T2 HUE045156 T2 HU E045156T2 HU E14819084 A HUE14819084 A HU E14819084A HU E14819084 A HUE14819084 A HU E14819084A HU E045156 T2 HUE045156 T2 HU E045156T2
Authority
HU
Hungary
Prior art keywords
dosage forms
pharmaceutical dosage
pharmaceutical
forms
dosage
Prior art date
Application number
HUE14819084A
Other languages
English (en)
Hungarian (hu)
Inventor
Suzie Ribeiro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE045156T2 publication Critical patent/HUE045156T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14819084A 2013-12-13 2014-12-11 Gyógyászati dózisformák HUE045156T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13

Publications (1)

Publication Number Publication Date
HUE045156T2 true HUE045156T2 (hu) 2019-12-30

Family

ID=52146563

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14819084A HUE045156T2 (hu) 2013-12-13 2014-12-11 Gyógyászati dózisformák

Country Status (33)

Country Link
US (3) US10278969B2 (OSRAM)
EP (2) EP3597179B1 (OSRAM)
JP (2) JP6522619B2 (OSRAM)
KR (1) KR102349893B1 (OSRAM)
CN (2) CN105813635A (OSRAM)
AR (1) AR098716A1 (OSRAM)
AU (1) AU2014362999B2 (OSRAM)
CA (1) CA2930055C (OSRAM)
CL (1) CL2016001436A1 (OSRAM)
CY (1) CY1122063T1 (OSRAM)
DK (1) DK3079667T3 (OSRAM)
EA (1) EA036288B1 (OSRAM)
EC (1) ECSP16060194A (OSRAM)
ES (1) ES2745983T3 (OSRAM)
HR (1) HRP20191691T1 (OSRAM)
HU (1) HUE045156T2 (OSRAM)
IL (1) IL245705B (OSRAM)
LT (1) LT3079667T (OSRAM)
MA (1) MA39175A1 (OSRAM)
MX (1) MX2016007652A (OSRAM)
MY (1) MY194303A (OSRAM)
NZ (2) NZ719865A (OSRAM)
PE (1) PE20160851A1 (OSRAM)
PH (1) PH12016501039B1 (OSRAM)
PL (1) PL3079667T3 (OSRAM)
PT (1) PT3079667T (OSRAM)
RS (1) RS59270B1 (OSRAM)
SG (1) SG10202104627UA (OSRAM)
SI (1) SI3079667T1 (OSRAM)
TN (1) TN2016000207A1 (OSRAM)
TW (2) TWI800759B (OSRAM)
WO (1) WO2015087283A1 (OSRAM)
ZA (1) ZA201603064B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105813635A (zh) 2013-12-13 2016-07-27 诺华股份有限公司 药物剂型
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
US20240009193A1 (en) * 2020-12-18 2024-01-11 Qed Therapeutics, Inc. Methods of treating achondroplasia
AU2022236428A1 (en) * 2021-03-17 2023-11-02 Laboratoires Juvise Pharmaceuticals Pharmaceutical dosage system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
RU2014103250A (ru) 2011-07-01 2015-08-10 Новартис Аг Комбинированная терапия
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
CN105813635A (zh) 2013-12-13 2016-07-27 诺华股份有限公司 药物剂型
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
CN107787226A (zh) 2015-03-25 2018-03-09 诺华股份有限公司 药物组合
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS

Also Published As

Publication number Publication date
PL3079667T3 (pl) 2020-02-28
NZ719865A (en) 2022-07-29
CN116942629A (zh) 2023-10-27
SI3079667T1 (sl) 2019-10-30
PT3079667T (pt) 2019-10-10
US10278969B2 (en) 2019-05-07
CA2930055A1 (en) 2015-06-18
TWI721938B (zh) 2021-03-21
AU2014362999B2 (en) 2017-10-12
TN2016000207A1 (en) 2017-10-06
AR098716A1 (es) 2016-06-08
TW202128137A (zh) 2021-08-01
IL245705A0 (en) 2016-07-31
DK3079667T3 (da) 2019-09-09
EP3597179B1 (en) 2024-04-03
CN105813635A (zh) 2016-07-27
EP3597179A1 (en) 2020-01-22
LT3079667T (lt) 2019-09-10
SG10202104627UA (en) 2021-06-29
EP3079667A1 (en) 2016-10-19
KR102349893B1 (ko) 2022-01-10
US11160804B2 (en) 2021-11-02
AU2014362999A1 (en) 2016-05-26
JP6522619B2 (ja) 2019-05-29
JP2017502941A (ja) 2017-01-26
ECSP16060194A (es) 2019-07-31
EA036288B1 (ru) 2020-10-22
US20220265651A1 (en) 2022-08-25
ZA201603064B (en) 2017-07-26
CA2930055C (en) 2023-07-04
PH12016501039B1 (en) 2024-01-19
EP3079667B1 (en) 2019-06-26
HRP20191691T1 (hr) 2019-12-27
ES2745983T3 (es) 2020-03-04
IL245705B (en) 2021-05-31
US20170007602A1 (en) 2017-01-12
NZ760002A (en) 2022-07-29
HK1223833A1 (en) 2017-08-11
MX2016007652A (es) 2016-10-13
RS59270B1 (sr) 2019-10-31
TW201605494A (zh) 2016-02-16
CY1122063T1 (el) 2020-11-25
JP2019142927A (ja) 2019-08-29
EA201691231A1 (ru) 2016-10-31
MY194303A (en) 2022-11-27
PH12016501039A1 (en) 2016-07-04
JP6804585B2 (ja) 2020-12-23
CL2016001436A1 (es) 2017-02-10
PE20160851A1 (es) 2016-09-14
US20200054632A1 (en) 2020-02-20
TWI800759B (zh) 2023-05-01
MA39175A1 (fr) 2017-10-31
KR20160096093A (ko) 2016-08-12
WO2015087283A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
CY1127391T1 (el) Σχηματα δοσολογιας ανοσοσυζευγματος εναντι- folr1
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112016009485A2 (pt) Inalador de medicamento
HUE037275T2 (hu) Gyógyszer-kombináció
DK3062849T3 (da) Medikamentadministrationsanordning
EP2972351A4 (en) IMPROVED TEST PROCEDURES
EP3750590C0 (en) THRESHOLD RELEASE ADMINISTRATION CAPSULE
DK3038674T3 (da) Medikamentafgivelsesindretning
DOS2013000177S (es) Capsulas
DK3590499T3 (da) Inhalerbare lægemidler
LT3035885T (lt) Inhaliatorius
DK3035886T3 (da) Inhalator
DK3043845T3 (da) Lægemiddelfremføringsanordning
LT3035887T (lt) Inhaliatorius
DK2964193T3 (da) Lægemidler til oral indgivelse
IL245705A0 (en) Pharmaceutical dosage forms
DK3003401T3 (da) Farmaceutisk præparat
LT3046537T (lt) Farmacinis angliavandenių preparatas, skirtas terapiniam panaudojimui
DK2897588T3 (da) Inhalerbart lægemiddel
EP3043648C0 (en) PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE
DK2983747T3 (da) Lægemiddelindgivelsesindretning
HRP20171888T1 (hr) Farmaceutski pripravci
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม
TH1401004646B (th) องค์ประกอบทางเภสัชกรรมชนิดรับประทาน